{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:00:08Z","timestamp":1787166008721,"version":"build-2736575974"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Information on immune checkpoint inhibitor-induced vasculitides is limited, and predictors for this condition have not been identified. Therefore, we have examined the frequency of immune checkpoint inhibitor-induced vasculitides by analyzing the data recorded in the Japanese Adverse Drug Event Report database. Data from April 2004 to March 2020 were extracted, and vasculitides as an immune-related adverse event was defined according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Adverse event signals were recognized as significant when the reporting odds ratio estimates and lower limits of the corresponding 95% confidence intervals exceeded 1. The use of nivolumab showed a significant signal for vasculitides. Furthermore, significant signals of polymyalgia rheumatica were found when the patients were treated with nivolumab, pembrolizumab, and ipilimumab. In addition, the frequencies of nivolumab- and pembrolizumab-induced polymyalgia rheumatica were higher in patients aged \u226570\u00a0years and female patients, respectively. Polymyalgia rheumatica was reported in 38 patients treated with nivolumab; 31 (82%) of these were either in recovery or in remission. Further, polymyalgia rheumatica was reported in 17 patients treated with pembrolizumab; 13 (76%) of these were in recovery or remission, while three (18%) were not. Polymyalgia rheumatica was reported in 12 patients treated with ipilimumab; seven (58%) of these were in recovery or remission. Our study highlights that careful monitoring for the symptom of PMR (e.g., bilateral pain in shoulder and pelvic girdles) is required when the patients are aged &amp;gt;70\u00a0years and have been treated with nivolumab and when the patients are women and have been treated with pembrolizumab.<\/jats:p>","DOI":"10.3389\/fphar.2022.803706","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T15:07:40Z","timestamp":1648566460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database"],"prefix":"10.3389","volume":"13","author":[{"given":"Koki","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenao","family":"Koseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotake","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40780-016-0048-5","article-title":"Analysis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Using the Japanese Adverse Drug Event Report Database","volume":"2","author":"Abe","year":"2016","journal-title":"J. Pharm. Health Care Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00296-020-04665-7","article-title":"Immune Checkpoint Inhibitor-Induced Musculoskeletal Manifestations","volume":"41","author":"Angelopoulou","year":"2021","journal-title":"Rheumatol. Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid Arthritis and Polymyalgia Rheumatica Occurring after Immune Checkpoint Inhibitor Treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2174\/1574886313666180508122332","article-title":"Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature","volume":"13","author":"Benfaremo","year":"2018","journal-title":"Curr. Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/cji.0000000000000163","article-title":"Nivolumab Causing a Polymyalgia Rheumatica in a Patient with a Squamous Non-small Cell Lung Cancer","volume":"40","author":"Bernier","year":"2017","journal-title":"J. Immunother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S555","DOI":"10.1097\/rhu.0000000000001012","article-title":"Immune Checkpoint Inhibitor-Associated Polymyalgia Rheumatica\/Giant Cell Arteritis Occurring in a Patient after Treatment with Nivolumab","volume":"27","author":"Betrains","year":"2019","journal-title":"J. Clin. Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-small-cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/jco.2009.26.7609","article-title":"Phase I Study of Single-Agent Anti-programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamadermatol.2020.2149","article-title":"Association of Anti-programmed Cell Death 1 Antibody Treatment with Risk of Recurrence of Toxic Effects after Immune-Related Adverse Events of Ipilimumab in Patients with Metastatic Melanoma","volume":"156","author":"Brunot","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline Gut Microbiota Predicts Clinical Response and Colitis in Metastatic Melanoma Patients Treated with Ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis Associated with Immune Checkpoint Inhibitors-A Systematic Review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the Management of Polymyalgia Rheumatica: a European League against Rheumatism\/American College of Rheumatology Collaborative Initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 Antibody-Induced Lupus Nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00262-020-02663-z","article-title":"Body Mass index and Immune-Related Adverse Events in Patients on Immune Checkpoint Inhibitor Therapies: a Systematic Review and Meta-Analysis","volume":"70","author":"Guzman-Prado","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1248\/bpb.b16-00765","article-title":"Factorial Analysis of Hepatitis B Virus Reactivation-Induced Hepatitis B Using JADER","volume":"40","author":"Hara","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0182045","DOI":"10.1371\/journal.pone.0182045","article-title":"Thromboembolic Adverse Event Study of Combined Estrogen-Progestin Preparations Using Japanese Adverse Drug Event Report Database","volume":"12","author":"Hasegawa","year":"2017","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1001\/archinternmed.2009.352","article-title":"Treatment of Polymyalgia Rheumatica: a Systematic Review","volume":"169","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0172057","DOI":"10.1371\/journal.pone.0172057","article-title":"Analysis of Factors Associated with Hiccups Based on the Japanese Adverse Drug Event Report Database","volume":"12","author":"Hosoya","year":"2017","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1248\/yakushi.18-00161","article-title":"Effectiveness of a Low-Dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment","volume":"139","author":"Imai","year":"2019","journal-title":"Yakugaku Zasshi"},{"key":"B23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1253\/circj.CJ-19-0773","article-title":"JCS 2017 Guideline on Management of Vasculitis Syndrome - Digest Version","volume":"84","author":"Isobe","year":"2020","journal-title":"Circ. J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.amjms.2021.04.010","article-title":"Nivolumab-induced Polymyalgia Rheumatica in a Patient with Lung Adenocarcinoma","volume":"362","author":"Kita","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.31138\/mjr.32.3.218","article-title":"Should We Be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-existing Rheumatic Diseases? Immunotherapy in Pre-existing Rheumatic Diseases","volume":"32","author":"Klavdianou","year":"2021","journal-title":"Mediterr. J. Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/art.20966","article-title":"A New Haplotype of PDCD1 Is Associated with Rheumatoid Arthritis in Hong Kong Chinese","volume":"52","author":"Kong","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/jco.2017.77.0305","article-title":"Safety of Programmed Death-1 Pathway Inhibitors Among Patients with Non-small-cell Lung Cancer and Preexisting Autoimmune Disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s10753-013-9718-8","article-title":"Expression of Programmed Death-1 (PD-1) on CD4+ and CD8+ T Cells in Rheumatoid Arthritis","volume":"37","author":"Li","year":"2014","journal-title":"Inflammation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1244","DOI":"10.1002\/cnr2.1244","article-title":"Polymyalgia Rheumatica in a Melanoma Patient 11 Months after Completion of Immunotherapy with Nivolumab","volume":"3","author":"Lobo","year":"2020","journal-title":"Cancer Rep. (Hoboken)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e000750","DOI":"10.1136\/jitc-2020-000750","article-title":"Checkpoint Inhibitor-Related Renal Vasculitis and Use of Rituximab","volume":"8","author":"Mamlouk","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/medicines7110068","article-title":"Identification and Classification of Polymyalgia Rheumatica (PMR) and PMR-like Syndromes Following Immune Checkpoint Inhibitors (ICIs) Therapy: Discussion Points and Grey Areas Emerging from a Systematic Review of Published Literature","volume":"7","author":"Manzo","year":"2020","journal-title":"Medicines (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"Itc65","DOI":"10.7326\/aitc201705020","article-title":"Polymyalgia Rheumatica","volume":"166","author":"Matteson","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory Monoclonal Antibodies for Cancer Therapy","volume":"7","author":"Melero","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 Therapy in Patients with Advanced Melanoma and Preexisting Autoimmune Disorders or Major Toxicity with Ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s00432-017-2410-x","article-title":"Polymyalgia Rheumatica in a Melanoma Patient Due to Nivolumab Treatment","volume":"143","author":"Nakamagoe","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma without BRAF Mutation","volume":"372","author":"Robert","year":"","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/s1470-2045(18)30608-9","article-title":"Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors: an Observational, Retrospective, Pharmacovigilance Study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia Rheumatica and Giant-Cell Arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/art.1780380311","article-title":"Epidemiology of Polymyalgia Rheumatica in Olmsted County, Minnesota, 1970-1991","volume":"38","author":"Salvarani","year":"1995","journal-title":"Arthritis Rheum."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1248\/bpb.b19-00105","article-title":"Analyses of Respiratory Depression Associated with Opioids in Cancer Patients Based on the Japanese Adverse Drug Event Report Database","volume":"42","author":"Sugawara","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"B45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/art.40375","article-title":"Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"70","author":"Sunderk\u00f6tter","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.31557\/apjcp.2020.21.6.1697","article-title":"Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors","volume":"21","author":"Takada","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"B47","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/ijc.30501","article-title":"Safety and Efficacy of Nivolumab in the Treatment of Cancers: A Meta-Analysis of 27 Prospective Clinical Trials","volume":"140","author":"Tie","year":"2017","journal-title":"Int. J. Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.803706\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T15:07:42Z","timestamp":1648566462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.803706\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":48,"alternative-id":["10.3389\/fphar.2022.803706"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.803706","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"article-number":"803706"}}